Wave Life Sciences Ltd. Ordinary Shares (WVE) Stock
NASDAQ · WVE
3.66
Fundamentals
Market cap
$744.84M
Price / Earnings ratio
-3.9x
Price / Sales ratio
11.9x
Price / Book ratio
1.7x
Return on assets
-43.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

24/7 Wall Street
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
NeutralWVEAugust 13, 2026
24/7 Wall StreetNeutral
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
WVE

MarketBeat
WAVE Life Sciences Q2 Earnings Call Highlights
NeutralWVEJuly 30, 2026
MarketBeatNeutral
WAVE Life Sciences Q2 Earnings Call Highlights
WVE

Zacks Investment Research
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
NeutralWVEJuly 30, 2026
Zacks Investment ResearchNeutral
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
WVE

Zacks Investment Research
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
NeutralWVEJuly 22, 2026
Zacks Investment ResearchNeutral
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
WVE
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy4
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
51M34M17M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
766M506M253M0
Revenue to Profit
2025$42.7M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-204.4M
Net incomeEarnings
EPS forecast
Actual EPS
$-0.32
Q1FY26
$-0.33
Q2FY26
The market is expecting earnings per share of -$0.33 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

24/7 Wall Street
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
NeutralWVEAugust 13, 2026
24/7 Wall StreetNeutral
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
WVE

MarketBeat
WAVE Life Sciences Q2 Earnings Call Highlights
NeutralWVEJuly 30, 2026
MarketBeatNeutral
WAVE Life Sciences Q2 Earnings Call Highlights
WVE

Zacks Investment Research
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
NeutralWVEJuly 30, 2026
Zacks Investment ResearchNeutral
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
WVE

Zacks Investment Research
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
NeutralWVEJuly 22, 2026
Zacks Investment ResearchNeutral
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
WVE

Zacks Investment Research
New Strong Buy Stocks for July 22nd
NeutralWVEJuly 22, 2026
Zacks Investment ResearchNeutral
New Strong Buy Stocks for July 22nd
WVE

Zacks Investment Research
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
NeutralWVEJuly 20, 2026
Zacks Investment ResearchNeutral
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
WVE

Zacks Investment Research
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
NeutralWVEJuly 1, 2026
Zacks Investment ResearchNeutral
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
WVE

Zacks Investment Research
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
NeutralWVEJune 16, 2026
Zacks Investment ResearchNeutral
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
WVE

Stocktwits
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug
NeutralWVEMay 18, 2026
StocktwitsNeutral
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug
WVE

Zacks Investment Research
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
NeutralWVEApril 28, 2026
Zacks Investment ResearchNeutral
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
WVE
About Wave Life Sciences Ltd. Ordinary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees317
CEODr. Paul B. Bolno M.B.A., M.D.
IPO DateNov 11, 2015
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Paul B. Bolno M.B.A., M.D. | President, CEO & Director | 1974 |
| Dr. Gregory L. Verdine Ph.D. | Founder & Director | 1959 |
| Mr. Kyle B. Moran CFA | CFO & Principal Accounting Officer | 1971 |
| Dr. Chandra Vargeese Ph.D. | Chief Technology Officer | 1961 |
| Dr. Christopher Francis Ph.D. | Senior VP of Corporate Development & Head of Emerging Areas | 1978 |
| Dr. Erik Ingelsson M.D., Ph.D. | Chief Scientific Officer | — |
| Ms. Linda Rockett J.D. | Senior VP & General Counsel | — |
Fundamentals
Valuation
Market cap$744.84M
Price-to-sales ratio11.94
Price-to-book value1.72
Price-earnings ratio-3.90
Return on Equity-57.00%
Return on Sales-256.00%
Return on Assets-43.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-1.08
Income Statement
Average volume3,185,048
EBITDA$-174.59M
1 year high (52w)$21.73
1 year low (52w)$3.82
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
5 Wall Street Analyst Ratings
BUY
80% Buy
20% Hold
0% Sell
Target price
$19.00
Est return
420.55%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.2 | -4.4 | -18.1 | -14.4 | ||||||||
| 2022 | -32.6 | +4.7 | -16.3 | -3.9 | -24.7 | +153.9 | -20.1 | +24.3 | +22.8 | +35.3 | -11.9 | +60.9 |
| 2023 | -20.5 | -17.8 | +3.1 | -13.8 | +3.4 | -12.5 | +22.8 | -0.5 | +26.7 | -10.6 | +0.2 | -8.3 |
| 2024 | -19.1 | +20.2 | +20.3 | -21.9 | +9.0 | -20.0 | +26.1 | -6.8 | +47.7 | +65.2 | +9.2 | -19.0 |
| 2025 | -13.1 | -10.9 | -19.6 | -0.3 | -24.3 | +4.0 | +24.2 | +11.2 | -23.9 | +28.6 | -6.6 | +129.4 |
| 2026 | -18.9 | +3.7 | -47.7 | +3.4 | -10.1 | -7.2 | -5.7 | -14.6 | -23.9 |



